About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

351,441 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 09/21/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 09/21/2020.
  • Chimeric Antigen Receptor (CAR) T Cells

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

     

    CAR T cell therapy utilizes autologous T cells from a patient that have been modified with a chimeric antigen receptor (CAR).1 CARs are composed of an antigen-recognition domain, which is most often a single-chain variable fragment derived from a monoclonal antibody or an antigen-binding fragment, fused to signaling domains designed to redirect T cell function.1,2 CARs can allow the modified patient T cells to recognize tumor-cell antigens and initiate an immunologic response.1-3 Tumor cells are either targeted directly by CAR-modified T cells or through recruitment of other components of the immune system.1

    See below for a depiction of the CAR T cell engineering process and description of identified targets (B-cell maturation antigen [BCMA] in multiple myeloma and CD19 in non-Hodgkin lymphoma).

    Preclinical studies have demonstrated the activity of the CAR T cell approach.22,23 Various CAR T cell therapies are currently being investigated for the treatment of hematologic malignancies and solid tumors.

    Celgene is developing CAR T cell therapies, including a collaboration with bluebird bio.

    View Related Molecules

    References

    1. Davila ML, et al. Int J Hematol. 2014;99:361-371. PMID: 24311149
    2. Davila ML, et al. Oncoimmunology. 2012;1:1577-1583. PMID: 23264903
    3. Mato A, Porter DL. Blood. 2015;126:478-485. PMID: 26065655
    4. Raje N, et al. J Clin Oncol. 2018;36:15_suppl
    5. NCI Drug Dictionary. www.cancer.gov/publications/dictionaries/cancer-drug/def/bcma-specific-car-expressing-t-lymphocytes
    6. Shah N, et al. Blood. 2018;132:488.
    7. NCI Drug Dictionary. www.cancer.gov/publications/dictionaries/cancer-drug/def/791258
    8. Mailankody S, et al. Blood. 2018;132:957.
    9. NCI Drug Dictionary. www.cancer.gov/publications/dictionaries/cancer-drug/def/792482
    10. Dotti G, et al. Immunol Rev. 2014;257:107-26. PMID: 24329793
    11. Bridgeman JS, et al. Clin Exp Immunol. 2014;175:258-267. PMID: 24116999
    12. Maus MV and June CH. Clin Cancer Res. 2016;22:1875-1884. PMID: 27084741
    13. Kawaleker OU, et al. Immunity. 2016;44:712. PMID: 28843072
    14. Seckinger A, et al. Cancer Cell. 2017;31:396-410. PMID: 28262554
    15. Tai Y-T, et al. Immunotherapy. 2015;7:1187-1199. PMID: 26370838
    16. Carpenter RO, et al. Clin Cancer Res. 2013;19:2048-2060. PMID: 23344265
    17. Abramson JS, et al. J Clin Oncol. 2018;36(suppl)[abstract 7507].
    18. Siddiqi T, et al. Blood 2018;132:300.
    19. NCI Drug Dictionary. www.cancer.gov/publications/dictionaries/cancer-drug/def/778386
    20. Makita S, et al. Cancer Sci. 2017;108:1109-1118. PMID: 28301076
    21. Wang K, et al. Exp Hematol Oncol. 2012;1:36. PMID: 23210908
    22. Kowolik CM, et al. Cancer Res. 2006;66:995-1004. PMID: 17108138
    23. Brentjens RJ, et al. Clin Cancer Res. 2007;13:5426-5435. PMID: 17855649